Scancell Holdings plc (AIM: SCLP), a developer of immunotherapies for the treatment of cancer, on Monday reported positive data from the ongoing SCOPE trial for SCIB1 in combination with ipilimumab and nivolumab in advanced melanoma patients.
At the 25-week milestone, 80% of the 25 patients in cohort 1 showed progression-free survival (PFS), with 20% achieving complete response (CR). The disease control rate (DCR) reached 84%, and the objective response rate (ORR) was 72%. These results compare favourably to the double checkpoint inhibitors alone, where PFS was 65%, CR was 16%, DCR was 58%, and ORR was 48%.
Cohort 1 has enrolled 42 out of 43 patients, with all expected to reach week 25 by H1 2025. Additionally, cohorts 2 and 3 are progressing, focusing on SCIB1 combined with pembrolizumab and the next-generation iSCIB1+ with ipilimumab and nivolumab, respectively. The data will inform the selection of the optimal vaccine for future phase 2/3 trials.
Scancell is advancing its immunotherapy pipeline, leveraging platforms like ImmunoBody and AvidiMab to target cancer with novel vaccines and monoclonal antibodies. The SCOPE trial aims to establish SCIB1 and iSCIB1+ as effective additions to standard checkpoint inhibitor therapies.
hVIVO completes pilot study for hMPV challenge model
Merck's Gardasil approved for males in China
Brii Bio acquires BRII-179 IP rights
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Sanofi's combination vaccine candidates for flu and COVID-19 get Fast Track Designation
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine